purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation bntx earnings call period ending december image source motley fool biontech se bntx q earnings callmar etcontents prepared remark question answer call participant prepared remark operatorwelcome biontech fourthquarter fullyear earnings call would like hand call dr victoria meissner vice president strategy investor relation please go aheadvictoria meissner vice president strategy investor relation thank good morning good afternoon thank joining biontechs fourthquarter fullyear earnings call reminder slide using call corresponding press release issued morning found investor relation section website next slide see forwardlooking statement disclaimer additional information statement risk described filing yous security exchange commission forwardlooking statement call subject significant risk uncertainty speak date conference call undertake obligation update revise statementson slide find agenda today call today joined following member biontechs management team youğyou şahin ceo cofounder ozlem tureci chief medical officer cofounder jens holstein chief financial officer ryan richardson chief strategy officer would like hand ugur youğyou şahin cofounder chief executive officer thank victoria warm welcome joining u today slide let start reiterating vision company goal biontech founded year ago vision harness power immune system fight human disease particularly cancer emergence pandemic accelerates mission leading development covid vaccine achievement showcased versatility mrna technology also highlighted unique expertise ability execute fast vision realized broadened eliminating potential science across therapeutic area building three objective moving forward establish multiproduct company powered pioneering technology science address medical need worldwide contribute development innovative precision medicine cancer aiming multiple product approval coming year expand strengthen sustainable respiratory infectious disease vaccine business building success comirnaty franchise slide next slide want talk clinical achievement successfully advanced clinical pipeline enhanced technology platform digital capability infrastructure executing across key strategic initiative continue develop empower innovative oncology infectious disease pipeline today program oncology seven program infectious disease evaluated clinical trial including multiple phase phase clinical trial particularly excited recent achievement shaping oncology pipeline started seven clinical trial inlicensed six clinical asset throughout year importantly several asset advanced mid latestage development phase phase clinical trial ongoing trial feature antibodydrug conjugate mrna vaccine novel io therapy indication nonsmall cell lung cancer breast endometrial cancer adjuvant colorectal cancer adjuvant pancreatic cancer infectious disease started three firstinhuman phase clinical trial leveraging proprietary mrna vaccine technology including candidate evaluated shingle tuberculosis mpox course aim advance prioritize additional product candidate latestage development expect potential registration trial running slide field oncology currently undergoing significant shift away traditional chemotherapy toward combination therapy shift leverage power immunooncology antibodydrug conjugate potentially transform also advanced cancer manageable condition reflect achievement proudly say accelerated io adc program starting new task also successfully recruiting patient clinical trial across various indication testament hard work dedication team collaboration partner well trust willingness patient participate study looking ahead aim build success recruit patient clinical trial across indication lung cancer breast cancer colorectal cancer indication slide successfully executed strategic investment acquisition licensing agreement publicprivate partnership enabling continued progress toward building multiproduct aipowered patientcentric company since foundation placed strong emphasis computational medicine data science artificial intelligence machine learning acquisition instadeep integrating capability supercomputing ai research generative ai various process example identify optimize molecule predict biological clinical outcome speed workflow expanded technology base include adcs initiating new collaboration dualitybio medilink therapeutic believe adcs potential supplement replace highly toxic chemotherapy regimen new combination backbone cancer treatment collaboration oncoc biotheus complement toolkit technology nextgeneration io antibody offer unique mechanism action augmented oncology pipeline mid latestage clinical program started strongly collaboration front announcing strategic alliance autolus aimed advancing company autologous cart cell program toward commercialization collaboration support development commercialization autolus lead cell therapy candidate obecel retain option participate auto autong program importantly option use autolus commercial cell therapy manufacturing infrastructure costefficient manner relevance plan extend development bnt additional claudin positive tumor type thus realize full potential slide bnt cart cell therapy targeting claudin improve cart cell inaudible codeveloped cart cell amplifying rna vaccine carvac short bnt one example biontechs novel inaudible combination goal enhance persistence effector function cart cell repeated administration carvac recently presented data suggesting favorable effect carvac cart cell persistence clinical trial claudin tumor based promising early clinical result believe bnt potential make significant impact patient claudin positive tumor nearterm strategy establish claudin proven target solid tumor establish bnt first cart cell therapy gene cell tumor claudin expressed solid cancer including ovarian lung gastric pediatric cancer upcoming data inform development path tumor indication slide continue building portfolio compound class adjusted mechanism action including immunomodulators targeted therapy mrna vaccine believe combination therapy approved could play important role effort toward potentially curative approach would like thank confidence success continued support turn call ozlem speak oncology pipelineozlem tureci cofounder chief medical officer thank ugur glad speaking everyone today starting slide overview oncology pipeline partner reported data across portfolio multiple medical meeting including asco esmo published manuscript peerreviewed journal data readout expected year starting aacr bnt individualized neoantigenbased cancer vaccine adjuvant pdac bnt oftheshelf cancer vaccine nonsmall cell lung cancer advanced expanded pipeline considerably multiple mid latestage trial ongoing aim continue progress oncology pipeline toward pivotal data readout submission regulatory approval next month slide left ongoing trial mid latestage development three top list initiated bnt antictla io experience small cell lung cancer bnt antiher adc herlow breast cancer bnt individualized cancer vaccine adjuvant pancreatic cancer space right product candidate based adc io mrna cancer vaccine modality planning initiate additional phase phase trial program include validated novel target well inhouse inlicensed asset unique mode action believe multiple shot goal inlicensed asset starting contribute value creation toward derisking pipeline plan explore potential combination product candidate featuring asset based scientific rationale preclinical clinical evidence also thinking future treatment sequencing different indication provide option patient along disease journey shown slide began building pipeline adc candidate includes thirdgeneration adcs directed four distinct target four target collectively cover wide range cancer type reason adding modality clinical platform pipeline believe adcs transform oncology space become broadly used backbone combination treatment strategy acquiring specific asset based potentially differentiated profile objective covering multiple cancer type broad market may address bnt hertargeting adc advanced adc also one frontrunners clinical pipeline slide bnt thirdgeneration adc aim overcome drawback first second generation adcs achieve high stability circulation low risk target payload delivery high drug antibody ratio eight expanded therapeutic window comprised humanized antiher igg antibody covalently attached potent proprietary dna topoisomerase inhibitor via stable maleimide tetrapeptide linker selectively cleavable inaudible regulated tumor test bnt binding surface tumor cell inhibit signaling followed internalization adc receptor complex cleavage linker release membrane permeable payload effect killing tumor cell also bystander killing neighboring tumor cell regardless expression level preclinical study firstgeneration adcs animal model bnt observed higher stability lower level free payload circulation efficient payload release within tumor cell stronger antitumor activity including herlow model slide bnt currently evaluated signalseeking phase clinical trial expressing advanced solid tumor dose expansion part phase study enrolling pretreated patient advanced metastatic expressing solid tumor february year patient received bnt phase trial first data study presented asco last year reported preliminary antitumor activity heavily pretreated patient expressed solid tumor response observed patient treated different dose level different expression status based finding dark green marked cohort right initiated potentially registrational trial patient endometrial cancer breast cancer slide breast cancer cohort phase trial patient herpositive cancer mean high intermediate level expression showed objective response rate disease control rate patient refer low breast cancer particularly high medical need objective response rate thus disease control rate bnt observed well tolerated adverse event manageable interstitial lung disease grade occurred two patient based data initiated phase study bnt chemotherapynaive patient hormone receptor positive herlow breast cancer whose disease progressed prior endocrine therapy without cdk inhibition metastatic setting versus investigator charge chemotherapy shown slide yous youk eu japan approximately patient per year diagnosed breast cancer majority achieved remission surgery initial therapy get cured treated hormonal targeted therapy chemotherapy first generation targeting antibody benefited patient high intermediate expression level designated positive recently patient herlow expression comprise twothirds remaining breast cancer patient shown benefit substantially new generation hertargeted adc therapy herdirected adcs currently approved chemotherapy experienced patient meaning first line onwards ongoing phase study targeting chemonaive patient second line onwards marked dark green slide coming back phase trial finding endometrial cancer patient advanced recurrent metastatic herpositive herlow tumor endometrial cancer received fast track designation breakthrough designation fda september clinical data patient endometrial cancer presented asco annual meeting patient received one treatment line including immunotherapy antiher antibody endocrine therapy bnt show promising antitumor activity across different expression level including ihc expression low expression objective response rate pending confirmation disease control rate synthesis small data cutoff early draw conclusion le frequent treatment emergent adverse event teaes protracted manifestation safety profile manageable new safety signal observed slide patient advanced unresectable recurrent endometrial cancer receive treatment based molecular profile related clinical data support adding immunotherapy chemotherapy frontline treatment patient stage endometrial cancer dmmr status patient overexpress treated hertargeting therapy trastuzumab combination chemotherapy frontline treatment despite recent advancement frontline treatment patient relapse present targeted therapy approved patient progressed firstline treatment post tumor expressed patient population currently focusing bnt slide would like reemphasize aim advance key program latestage development aim contributing next generation oncology medicine could include candidate featured slide believe investment effort pave way initial wave oncology product launch onwards pas presentation cfo jens holsteinjens holstein chief financial officer thank ozlem warm welcome everyone today call another successful year biontech journey develop novel therapy cancer infectious disease let highlight three main point kept global covid vaccine market leadership grew advanced latestage pipeline delivered strong financial performance highlighted billion euro total recognized revenue billion euro profit tax resulting earnings per share fully diluted basis euro ended financial year approximately million euro cash cash equivalent security investment turning next slide financial performance strong able maintain profitability also financial challenge navigate thirdquarter earnings call last year updated fullyear covid vaccine revenue guidance around billion euro reflecting writedowns amount approximately million euro collaboration partner pfizer q pfizer recognized additional writedowns approximately million euro negatively impacted topline figure compared initial expectation q negative impact revenue accumulated total approximately million euro writedowns related eg inventory would typically negative impact gross profit pl following gross profit share agreement pfizer writedowns partner negative effect biontechs revenue figure made revenue guidance challenging said agreement important advantage biontech requires little commercial infrastructure covid vaccine franchise low expense related sale marketing comparison player field believe favorable comirnaty leading brand global covid vaccine market despite decrease revenue despite negative impact writedowns able remain profitable grew yearend financial position respect cash cash equivalent security investment billion euro compared billion euro end please note contractual settlement gross profit share temporal offset one calendar quarter addition pfizers financial quarter subsidiary outside united state differs moving summary financial result fourth quarter full year shown next slide three month ended december st recognized billion euro covid vaccine revenue compared billion euro comparative period financial year total reported revenue reached billion euro compared billion euro primarily driven lower covid vaccine market demand stated writedowns reported collaboration partner pfizer negatively influenced revenue moving cost sale cost sale amounted million euro fourth quarter line million euro comparative prioryear period financial year cost sale amounted close million euro compared approximately billion euro drop mainly caused decrease covid vaccine sale research development expense reached million euro fourth quarter compared million euro comparative period financial year research development expense amounted approximately billion euro compared billion euro increase mainly influenced progressing clinical study pipeline candidate well newly acquired product candidate development variantadapted covid vaccine line higher head count compared previous year example support existing clinical trial future growth initiative also saw respective higher cost wage benefit social security expense financial year general administrative expense amounted approximately million euro fourth quarter well comparative period financial year general administrative expense remained billion euro around level previous year slight increase ga mainly influenced increased expense service well wage benefit social security expense resulting increase headcount income tax accrued amount million euro fourth quarter compared million euro comparative period financial year income tax accrued amount million euro compared billion euro derived effective income tax rate financial year roughly line expectation around improved versus last year tax rate fourth quarter net profit reached million euro compared billion euro comparative period year ended december st net profit reached billion euro compared billion euro diluted earnings per share fourth quarter amounted euro compared euro comparative period financial year diluted earnings per share amounted euro compared euro let u continue next slide show financial guidance provided q earnings call november comparison actuals financial year starting top recognized billion euro covid vaccine revenue compared guidance around billion euro approximately million euro additional writedowns collaboration partner unexpectedly recognized q moving rd expense financial year rd expense nearly billion euro slightly amended guidance november billion euro lower spending example collaboration main contributor well strong cost control measure cord activity focused broadening accelerating existing pipeline product candidate oncology infectious disease line expectation moving sga expense financial year recognized million euro sga expense slightly lower end amended guidance million euro million euro closely monitoring spending reflect uncertainty revenue without jeopardizing future need area moving capex financial year capital expenditure operating activity amounted million euro whereof majority related investment building laboratory office facility mainz germany spending line expectation ranging million euro million euro lastly tax already mentioned financial year reached annual effective income tax rate roughly line amended guidance around turning next slide showing financial year guidance let highlight key aspect company outlook financial year starting total revenue biontech group expect total revenue range billion euro billion euro providing range estimate today take extent potential downside account example assume largely vaccination rate yous market seen price pressure yous q smaller inventory writedown collaboration partner pfizer faced additional writedowns previous announced one hit revenue q also assume generate revenue pandemic preparedness contract german government financial guidance expect rd expense range billion euro billion euro sga expense expected range million euro million euro please note anticipated expense related external legal advice connection legal litigation reflected sga operating expense additionally guidance include may impacted potential payment resulting collaboration agreement inlicensing deal transaction outcome ongoing future legal dispute related activity judgment settlement lastly capital expenditure financial year expected range million euro million euro increasing operating expense rd sga accelerate biontechs transition multiproduct oncology infectious disease company commercial footprint want increase investment lift potential value see portfolio product candidate inlicensed multiple asset bolster latestage pipeline year invest progressing candidate laterstage trial fuel biontechs next stage growth previously mentioned aim potentially registration clinical trial ongoing end paved way multiple potential product approval estimated begin first launch previously indicated transition year company continue invest longterm growth strategy maintaining strict cost discipline overall transition year revenue driven largely uptake covid vaccine second half consequence expected revenue range taking account cost sale rd expense expect profitable turning next slide today biontech leading profitable covid vaccine business see slide covid vaccine business benefited lean fixed cost structure generates attractive positive result coming year aim invest alongside partner bringing variant adapted potentially combination vaccine market goal contributing future value generation addition valuecontributing covid vaccine franchise investing longterm value creation multiple product oncology pipeline let highlight three value driver plan potentially registrational trial ongoing end aim first potential oncology launch adding top line thirdly believe diversified clinical pipeline offer multiple product growth opportunity year come summarizing believe covid vaccine franchise innovative pipeline product candidate drive longterm value creation company chief strategy officer ryan richardson talk strategic driver transformation thank youryan richardson chief strategy officer thank jens wrap prepared remark provide highlevel overview strategy path value creation mid latestage oncology pipeline program concluding important date mark calendar next slide highlight broad value creation opportunity underpinning strategy balance sheet strengthened continue serve strategic asset fuel longterm growth continue invest behind marketleading covid vaccine franchise leveraging partnership pfizer across rd manufacturing commercial function productcontribution basis expect franchise continue highly cash generative working pfizer develop covid influenza combination vaccine successful latestage trial could reach market early fall ramping investment expanding diverse latestage oncology pipeline goal least trial initiated registrational potential end year believe broad pipeline deliver multiple new commercial product launch year ahead finally continue invest industrialize mrna vaccine platform address infectious disease high unmet global need today five infectious disease vaccine beyond covid phase clinical trial aim bring first vaccine pipeline market complemented expanding latestage infectious disease vaccine pipeline strategy aim transform biontech diversified cash flowgenerating multiproduct company deliver sustained longterm growth turning next slide would like spend little time today growth potential expanding latestage pipeline pipeline includes seven mid latestage program currently phase trial mentioned goal plus trial registrational potential initiated end also expect busy calendar program update year include update several cancer vaccine program aacr announced last week anticipated update specific io adc program major medical conference throughout year therefore important year execution transition toward goal commercializing oncology portfolio looking forward sharing detail program throughout course year ultimately believe oncology pipeline deliver one indication launch per year onwards see significant potential mid latestage program address unmet medical need across broad range cancer type across cancer treatment continuum truly excited potential oncology pipeline hold expand improve cancer treatment option people around world closing would like highlight next slide important investor event holding year annual general meeting take place may th next innovation series event november th year also introduce new exciting event focused expanding work field artificial intelligence machine learning take place october st look forward sharing detail event near future would like thank shareholder continued support open floor question question answer operatorthank operator instruction go first question one moment please first question come line daina graybosch leerink partner please go aheaddaina graybosch leerink partner analyst yeah thank guy thanks update question look forward potential registrational trial wonder talk maybe even range revenue expectation could looking oncology portfolio followupryan richardson chief strategy officer yes thanks daina think pipeline quite broad one criterion common among asset list actually target multiple solid tumor mean actually peak sale estimate collection asset actually well billion range long term estimate long term think focused executing first launch think prepared yet give number think talking doubledigit indication address across solid tumor landscapedaina graybosch leerink partner analyst great thank followup specific autolus collaboration wonder could talk potential scenario see cart business autolus maturing advancing next five yearsryan richardson chief strategy officer sure start primary rationale autolus ended actually higher conviction moving forward aggressively bnt lead cell therapy cart program know targeting claudin mrna vaccine amplifier talked testicular cancer potential lead indication faster potential fasttomarket path given high unmet need refractory setting also seeing strong encouraging data indication refractory ovarian cancer even seeing response lung cancer claudin positive tumor autolus collaboration give u sort runway aggressively explore multiple pivotal trial parallel leveraging manufacturing infrastructure united state kite acquisition asset year ago also combined autolus stateoftheart manufacturing infrastructure united kingdom first rationale addition deal incorporates option could come pivotal trial stage couple autolus program find phase data cd encouraging early encouraging also gd car think interesting approach could complementary collaboration contstrict give u optionality actually scale multiproduct franchise cell therapy keeping fixed cost lean allowing u accelerate bnt forwarddaina graybosch leerink partner analyst greatoperatorthank go next question next question come line chris shibutani goldman sachs please go aheadunknown speaker hey steven chris thank taking question one financial side give little bit color driving increase sga guidance think midpoint increase prior year wondering related covid related building oncology franchise specifically adc talk type clinical profile would attractive herlow breast cancer indication thank youjens holstein chief financial officer yes thanks question take first one sga expense increase anticipate heard u planning launch potentially first product course got build infrastructure able commercialize compound coming onwards therefore intend invest infrastructure specifically also commercial setup yous going forwardozlem tureci cofounder chief medical officer second question make adc indication hormone receptor positive low breast cancer interesting get rightunknown speaker kind expectation type clinical profile would attractive spaceozlem tureci cofounder chief medical officer ttps adc think differentiable safety efficacy profile want see phase trial ongoingyouğyou şahin cofounder chief executive officer yeah add ozlem shared profile allowing u dose provide higher dos believe particularly important population around half herlow population particularly interesting interesting breast cancer well endometrial cancer herpositive tumor believe position product higher higher objective response rate plus higher durability pointunknown speaker ok thank much teamoperatorthank next question come line bill maughan canaccord please go aheadbill maughan canaccord genuity analyst good morning thanks kind twopart question ability maintain market share covid vaccine going forward wondering thinking ability guess defend andor grow given example know arcturus japan selfamplifying rna covid moderna previously made lot noise prefilled syringe know pfizer rolling prefilled syringe guess wondering widespread seen competitive advantage become available thank youryan richardson chief strategy officer yeah thank question believe still performed strong globally market share covid franchise see market share pressure couple market like united state point also market share gain number geography maintained high market share europe also grew market share country like japan actually pretty sizable volume perspective last month going feel confident continue maintain leadership position mark globally question competition yes expect new entrant mostly niche player peripheral market think pointed also role prefilled syrinx important point think last year fair say part reduction market share united state experienced due sort lack limited supply prefilled syrinx last year supply united state also singledose file well clearly market preference prefilled syrinx go taken step pfizer dramatically increase supply prefilled syrinx united state also elsewherebill maughan canaccord genuity analyst thank youoperatorthank next question come line akash tewari jefferies please go aheadivy wang jefferies analyst good morning ivy akash thanks taking question two first one covid covid vaccine gross margin given pfizer reported billion revenue versus billion splitting gross profit pfizer seems imply gross margin lower previous level around additional writeoff pfizer q additionally think view gross margin beyond covid business especially competitor seems talk higher gtn discount second question quickly pipeline guess encouraged early signal bnt consumer outside pancreatic read across pancreatic data presented aacr soon thanksjens holstein chief financial officer yes let take first question thanks question clarify pfizer know responsible commercialization comirnaty market exception germany turkey gross profit share methodology work way course whatever pfizer writing writeoffs inventory something going gross profit share reduce revenue figure trying highlight last quarter hit around million due procedure mean u basically profit u cog come across due manufacturing activity responsible limited compare margin development versus see margin really read pfizer reporting really number reportozlem tureci cofounder chief medical officer regard question bnt performance pdac encouraged surprised really encouraged also reason following data disclosure phase pdac trial initiated phase pdac trial adjuvant setting bnt enrolling patient result saw cancer type considered immune suppressive cold low tumor mutational load encouraging u also go cancer indication type immunological profile fact phase trial indication collected data support pdac finding currently compiling published manuscriptsivy wang jefferies analyst thanksoperatorthank next question come line yaron werber td cowenyaron werber td cowen analyst great good morning thanks taking couple question well maybe first one ongoing phase study dynastybreast talk little bit powering pfs sound like remember correctly chemo orr historically pfs showed orr sort depends chemo going kind determine kind study work maybe talk powering study maybe little bit share phase data pfs kind get sense expecting secondly curious huge pipeline already executed obviously continuing execute need grow company lot continue execute purpose potentially bd given much already thank youryan richardson chief strategy officer thanks yaron start second question come first think obviously active last year bd front bringing u six clinical stage near clinical stage asset going continue active yaron think would agree feel already actually broad toolkit allows u lot focused increasingly execution think going continue active bd probably active term number clinical stage asset looking bring board focus year going executing getting pivotal trial initiated enrolledyouğyou şahin cofounder chief executive officer yeah second question think second question better answered powerign hazard ratio usually around power give u study around patient enrolloperatorthank go next question next question come line etzer darout bmo capital please go aheadetzer darout bmo capital market analyst great thanks taking question one question bnt vegf pdl highlighted program sort prominently couple slide looking sort phase beyond wondered would providing clinical update program could expect see specific well sort potential path phase program indication specifically might able sort pursue molecule thank youyouğyou şahin cofounder chief executive officer yeah thank question indeed see number clinical trial update molecule notable indication remind everyone biospecific molecule pdl pd blocking antivegf arm seen far consistently number cohort objective response rate encouraging various indication also reported already first combination trial small cell lung cancer double negative breast cancer cancer patient really exciting indication high response rate range double negative breast cancer patient also response rate patient population negative immune infiltrates unusual checkpoint blockade believe molecule replicate molecule two indication small cell lung cancer double negative breast cancer also wider range indication result allowing u position molecule combination partner classical immune therapy even importantly adc portfolioetzer darout bmo capital market analyst thank youoperatorthank next question come line jessica fye jpmorgan please go aheadjessica fye jpmorgan chase company analyst hey guy good morning thanks taking question first topline guidance think previously talked roughly billioneuro top line couple month ago appreciate highlighting variable factor guidance expand assumption drove change second pipeline related space guy going watching destinybreast readout relates adc thank youjens holstein chief financial officer yeah let take first question broadened range felt topline guidance reflect assumption made respect vaccination rate price level currently seen significant aware comirnaty course significantly relevant also made assumption related inventory writeoffs back writeoffs got anticipate going forward done included assumption course also additional anticipated revenue related service business german pandemic preparedness contract hand finalizing currently government therefore feel driving basically broadening rangejessica fye jpmorgan chase company analyst really factored broadeningjens holstein chief financial officer upside downside mentioned try work course current assumption could vary time done yesjessica fye jpmorgan chase company analyst got itozlem tureci cofounder chief medical officer yes regard adc concept adcs molecule around great concept obvious excited adc molecule bnt partnered duality ugur pointed earlier herlow breast cancer looking making difference high medical need population also heard target hazard ratio targetingyouğyou şahin cofounder chief executive officer yeah course comment clinical price third partiesjessica fye jpmorgan chase company analyst thank youoperatorthank next question come line simon baker redburn please go aheadsimon baker redburn analyst thank taking question two quick one may rd guidance billion billion step plethora study running make perfect sense wondering new normal wondering could say anticipated level rd expense beyond finally awful lot deal activity radiopharmaceutical space late would interested get thought attractiveness modality thanks muchjens holstein chief financial officer yeah happy take first question pointed correctly course broadened portfolio latestage clinical trial running drive cost great extent going forward given guidance yet following year got bear u little bit course latestage clinical trial cost money carefully look invest money shown already sort range beginning reduced cost also reflecting pressure faced top line regarding covid revenue figure adjust level insecurity think part job manage cost course ongoing year invest area feel create value company value shareholder remains top list going forwardyouğyou şahin cofounder chief executive officer yeah second part question attractiveness radio inaudible would like say repeating oncology transformation see transformation ongoing next year transformation happens new concept one new concept targeting tumor cell bystander effect seeing radio inaudible targeting tumor cell plus additional bystander effect even pronounced adc field see really tremendous transformation oncology providing u opportunity open indication believe past patient offer patient anything offering opportunity treat patient advanced disease disease bring combination thereby ensure even patient advanced disease really get considerable clinical benefitsimon baker redburn analyst great thanks muchoperatorthank next question come line ellie merle ubs please go aheadunknown speaker hi sarah ellie thanks much taking question could remind u latest thinking could see data inest phase randomized trial hoping see would continue give guy confidence program moving forwardyouğyou şahin cofounder chief executive officer ok yeah shortly report inest data melanoma trial year latest second half year expect next update colorectal cancer study end unknown speaker great thanksoperatorthank go final question today final question come line manos mastorakis deutsche bank please go aheadmanos mastorakis deutsche bank analyst hello quick question u manos mastorakis deutsche bank wanted know first phase readout see rest portfolio beyond assuming nothing major please correct wrong thank youryan richardson chief strategy officer yeah thank manos talked couple different trial think could produce data ahead product approval successful includes phase randomized trial inest crc mentioned potential interim update second half early also talked bnt program refractory second thirdline endometrial cancer initial readout likely phase think could registrational potential data strong think obviously goal end year start many phase already started could data update well pipeline two would point tomanos mastorakis deutsche bank analyst thank youoperatorthank thank concludes today conference call operator signoff duration minutescall participantsvictoria meissner vice president strategy investor relationsuğyou şahin cofounder chief executive officerozlem tureci cofounder chief medical officerjens holstein chief financial officerryan richardson chief strategy officerdaina graybosch leerink partner analystunknown speakerbill maughan canaccord genuity analystivy wang jefferies analystyaron werber td cowen analystetzer darout bmo capital market analystjessica fye jpmorgan chase company analystsimon baker redburn analystmanos mastorakis deutsche bank analyst bntx analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool recommends biontech se motley fool disclosure policy